Neuralink, Elon Musk's startup, recently received authorization from the Food and Drug Administration (FDA), a regulatory body in the United States equivalent to Anvisa here in Brazil, to start clinical trials with brain implants in human beings.

The announcement was made by the company itself on Thursday night (5/25). On Twitter, the startup highlighted that this was the result of the work of the Neuralink team in collaboration with the FDA.
Neuralink believes that implant technology can help cure conditions such as obesity, depression, schizophrenia, autism and even serious brain injuries such as blindness and paralysis.
Through brain signals, these implants also have the potential to allow the sending of information to control electronic devices and even internet browsing, opening up a world of possibilities for the integration between the human brain and technology.

However, the journey to approval of clinical trials was not an easy one for Neuralink. The company faced significant challenges, including concerns about the implants' lithium battery, the potential for wires to migrate within the brain, and the complexity of safely removing the device without causing damage to brain tissue.

After an initial application was denied by the FDA in early 2022, Neuralink worked closely with the regulatory agency, overcoming these concerns and finally obtaining the necessary authorization to begin clinical trials.

While approval is an important milestone, Neuralink has not yet begun the recruitment process for clinical trial participants.

[produtos id="tecnologia"]